The popularity of Sildenafil initially sparked a period of growth for major pharmaceutical companies, but recent shifts present a murky outlook for shareholders. Off-patent alternatives are reducing profits, and https://philiptnky156469.blog2freedom.com/41281956/the-blue-pill-and-big-pharma-a-volatile-bet